Allergan, Inc.

Joan-En Lin

Patrick Michael Hughes

Thomas C Malone

Michael R Robinson

Thierry Nivaggioli

Lon T Spada

Scott M Whitcup

Wendy M Blanda

Jeffrey L Edelman

Jane-Guo Shiah

Gerald Woodrow DeVries

Guadalupe Ruiz

Devin F Welty

Werhner C Orilla

Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 10 days and one year or longer.

Intraocular drug delivery systems

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods

Growing community of inventors

Tustin, CA, United States of America

Joan-En Lin